Evidence map›Paper›PMID 38016020›Full record

ArticleThe Journal of infectious diseases2024

Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.

Annika Rössler, Ludwig Knabl, Antonia Netzl, David Bante, Wegene Borena, Dorothee von Laer, Derek J Smith, Janine Kimpel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annika RösslerInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Austria.
Ludwig KnablTyrolpath Obrist Brunhuber GmbH, Zams, Austria.
Antonia NetzlCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, United Kingdom.
David BanteInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Austria.
Wegene BorenaInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Austria.ORCID 0000-0001-8011-5825
Dorothee von LaerInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Austria.
Derek J SmithCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, United Kingdom.
Janine KimpelInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Austria.ORCID 0000-0002-5210-7905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed neutralizing antibodies in samples from ancestral + BA.1 and ancestral + BA.4/5 boosted individuals, collected around 5.5 months after booster. Titers of neutralizing antibodies generally decreased compared to a time point early after the bivalent booster immunization. This was more pronounced for individuals without infection history and for recently emerged Omicron variants.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 Vaccines

Identifiers

PMID38016020
PMCPMC10938204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.